S&P 500
7,582.20
+0.03%
Dow Jones
51,018.80
+0.58%
Nasdaq 100
30,344.40
+0.25%
Russell 2000
2,916.31
-0.54%
FTSE 100
10,378.60
-0.32%
Nikkei 225
66,231.90
+0.67%

Health and Healthcare

Dendreon Rises on Takeover Chatter (DNDN, LLY, AMGN)

Photo of Paul Ausick
By Paul Ausick Published

Author
Dendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the Eli Lilly & Co. (NYSE: LLY) takeover of ImClone, which only stokes the rumor mill.

Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.

Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Paul Ausick |

Dendreon Shares Still Rising (DNDN)

Shares of Dendreon Corp. (NASDAQ: DNDN) rose nearly 50% yesterday following an announcement that sales of the company’s prostate cancer…

Douglas A. McIntyre |

Short Sellers Help Push Dendreon Higher

Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that…

Jon C. Ogg |

Total Curve Ball for Prostate Cancer Field (DNDN, JNJ, MDVN)

Dendreon Corporation (NASDAQ: DNDN) may be losing its favor as the prostate cancer drug of choice.  That is at least…

Jon C. Ogg |

The Questionable Dendreon Buyout Incentive

Dendreon Corp. (NASDAQ: DNDN) is by almost all measurements nothing short of a total failure of a biotech or biohealth…

Douglas A. McIntyre |

Comment From The Stock Masters

All eyes are on Dendreon Corporation (DNDN) today and their shares have been halted ahead of their meeting with the…

Jon C. Ogg |

Medivation, A Pain in the Rear for Dendreon (MDVN, DNDN)

Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals.  It and partner Astellas in Japan showed very…

Jon C. Ogg |

Dendreon In Trouble

AuthorDendreon Corporation (NASDAQ: DNDN) is in trouble.  That is what the performance is telling investors.  The maker of Provenge as…

David J. Phillips |

Dendreon: Not Running Out Of Cash

In the last four months, Dendreon Corp. (DNDN) has shed almost 84 percent in market value as disgruntled investors washed…

Douglas A. McIntyre |

A Make or Break Week for Dendreon (DNDN)

Dendreon(DNDN-NASDAQ) is going to be one of "THE TOP ISSUES" this week.  The company will have and FDA review panel…

Top Gaining Stocks

Dell Technologies
DELL • Vol: 42,366,555
NetApp
NTAP • Vol: 15,911,807
ServiceNow
NOW • Vol: 68,243,561
IBM
IBM • Vol: 28,527,546
Hewlett Packard Enterprise
HPE • Vol: 86,996,387

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Clorox
CLX • Vol: 4,744,001
ResMed
RMD • Vol: 3,526,686
Intel
INTC • Vol: 191,680,425
Skyworks Solutions
SWKS • Vol: 5,407,806